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Introduction: Sarcopenia and Parkinson’s disease (PD) are both common age-related
syndromes, and there is preliminary evidence that the probability of the co-occurrence of
these syndromes within one individual is higher than expected. However, it is unclear to
date whether one of the syndromes induces the other, or whether there may be common
underlying causes. This pilot study thus aimed at investigating the association of the
features of increased risk for PD with early stage sarcopenia (ESS).
Method: Two hundred and fifty-five community-dwelling individuals were recruited from
the Tübinger evaluation of Risk factors for Early detection of NeuroDegeneration (TREND)
study. The following features that are associated with an increased risk for future PD were
evaluated: the motor part of the Unified PD Rating Scale (UPDRS-III), hyperechogenicity
of the substantia nigra, prevalence of lifetime depression, hyposmia, REM sleep behavior
disorder and the recently introduced probability score for prodromal PD. Sarcopenia was
defined according to the European Working Group on Sarcopenia in Older People, which
was adapted to this cohort of healthy adults. Multiple linear regression analysis was used
to identify associations of PD-related features with ESS.
Results: The UPDRS-III score was significantly associated with ESS. The result
remained significant after the adjustment for age, gender and physical activity. No
association was found between the other PD-related features and ESS.
Conclusion: The significant association of the UPDRS-III score with ESS in this cohort
might indicate a common and early pathway in both diseases and supports the existence
of an “extended neurodegenerative overlap syndrome.” Moreover, the potential of EES
to serve as a prodromal marker of PD should be evaluated in future studies.
Keywords: sarcopenia, neurodegenerative overlap syndrome, prodromal Parkinson’s disease, Unified PD Rating
Scale, motor unit number index
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INTRODUCTION
Parkinson’s disease (PD) is the second most common
neurodegenerative disease and is characterized, among other
symptoms, by bradykinesia, rigidity, tremor and postural
instability. The social and economic burden of this age-related
disease is high, and the etiology and pathogenesis are only
partly understood. In addition to age, male gender, a positive
family history for PD and a hyperechogenicity of the substantia
nigra (SN+) are risk markers of the disease. Moreover, motor
and non-motor prodromal markers occur regularly in PD.
In more detail, PD encompasses a prodromal phase of many
years or even decades (Gaenslen et al., 2011). During this
prodromal phase, there is an increased probability of the
occurrence of non-motor features, such as hyposmia, minor
and major depression and REM sleep behavior disorder (RBD).
During the final years prior to the conversion to clinically
overt PD, also subtle motor features not sufficient for diagnosis
but still suggestive for the disease are more common in the
prodromal phase of PD than in the older population without
PD (Schrag et al., 2015). This has been shown for distal as
well as for axial motor symptoms such as gait and balance
(Maetzler and Hausdorff, 2012). This increased probability of
the occurrence of PD-related subtle motor symptoms in the
prodromal phase of the disease has also been demonstrated
with the use of the motor part of the Unified PD Rating Scale
(UPDRS-III) in a longitudinal study (Postuma et al., 2012). The
Movement Disorder Society (MDS) has recently introduced
a probability score for prodromal PD by considering all
currently known risk and prodromal markers of PD. This score
basically reflects the likelihood of prodromal PD being present
(Berg et al., 2015).
Sarcopenia, defined as age-related loss of muscle mass and
function, is also increasingly realized as a serious medical and
economic problem in our aging societies (Cruz-Jentoft et al.,
2010). Sarcopenia is evident in approximately 20% of individuals
over 70 years old; this figure rises to 50% in the over-80 age
group (Cruz-Jentoft et al., 2010). The pathways that lead to
sarcopenia have not yet been identified. The prevailing concept
for the development of sarcopenia is multifactorial (Cruz-Jentoft
et al., 2010). Previous investigations have identified a relationship
between a low number of motor neurons, as measured with the
motor unit number index (MUNIX), and sarcopenia (Drey et al.,
2014). Thus, neurodegeneration appears to play a role in the
onset of sarcopenia.
There is some evidence that at least a proportion of PD and
sarcopenia patients share a common pathway of dopaminergic
dysfunction and reduced numbers of motor neurons. Caviness
and co-authors have found significantly lower motor unit
numbers in the handmuscles of PD patients compared to healthy
controls using different MUNE (Motor unit number estimation)
techniques, a measure that is comparable to MUNIX (Caviness
et al., 2002). In summary, these findings suggest that a common
pathway exists at least in subpopulations of both diseases.
We followed this hypothesis by comparing respective
parameters in a random subsample of participants of the TREND
study (Tübinger evaluation of Risk factors for Early detection of
NeuroDegeneration), a cohort of individuals with and without
widely accepted risk factors for neurodegeneration.
METHODS
Participants
For this analysis, a random sample of 255 individuals who
were recruited during the second follow-up of the TREND
study were assessed with routine follow-up assessments and
Bioelectrical Impedance Analysis (BIA). TREND is designed as
a prospective biannual longitudinal study that aims to define
screening batteries for an earlier diagnosis of PD and Alzheimer’s
disease (http://www.trend-studie.de). The ethical committee of
the Medical Faculty of Tuebingen approved the study protocol,
and written informed consent was obtained from all participants.
Measured Values
PD-Associated Measurements
SN+ was measured via transcranial ultrasound. A value
of ≥0.22 mm2 was defined as hyperechogenicity. Olfaction
was investigated using the 16-item Sniffin’ sticks (Burghart
Medizintechnik, Germany) identification battery with normative
age-dependent cut-off values. Individuals below the 10th
percentile were classified as hyposmic. Depression was defined
by either a positive history of lifetime depressive episode
or a value of ≥18 points in the actual assessment of the
Becks Depression Inventory (BDI). RBD was diagnosed if the
criteria of the International Classification for Sleep Disorders
(ICSD) were met. The symptoms were assessed with the
RBD Screening Questionnaire (RBDSQ). The overall probability
of being in a prodromal PD phase was assessed with a
score recently introduced by the MDS, including in the
calculation the following features: age, gender, smoking history,
positive family history for PD, SN+, RBD, new version of
the UPDRS-III (MDS UPDRS-III) score >3 excluding action
tremor, hyposmia, constipation, symptomatic hypotension,
severe erectile dysfunction, urinary dysfunction and depression
(Berg et al., 2015). Motor features were measured with the MDS
UPDRS-III score alone. The scale consists of 18 items that rate
PD-specific motor features, such as rigidity, tremor, axial and
distal bradykinesia, facial expression, and postural deficits. Each
item has a score from 0 to 4. It should be noted that this test does
not include muscle strength and muscle mass assessments and
thus does not overlap with the sarcopenia assessment.
Sarcopenia-Associated Measurements
Muscle mass was calculated using Janssen’s regression formula by
applying BIA (Janssen et al., 2000). Isometric hand grip strength
was determined by using a hand-held dynamometer (JAMAR,
USA). Gait speed was measured by recording the time that was
required for participants to walk along a 20m hallway with a
stop watch. Physical activity was assessed by asking participants
for the duration of sports activity in hours per week. Activity
was scaled from “no sport = 5” till “more than 4 h per week =
1.” As the TREND cohort is basically a relatively “young” and
population-based cohort, the usual sarcopenia criteria could not
be applied due to a floor effect. Therefore, we defined early stage
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sarcopenia (ESS) in our cohort in participants who exhibited
muscle mass index (kg/m2), grip strength (kg), and gait speed
(m/s) values that were in the lower half of the scales. According
to the European Working Group on Sarcopenia in Older People
(EWGSOP) criteria (Cruz-Jentoft et al., 2010), the combination
of a low muscle mass index AND a low grip strength OR a low
gait speed led to classification of ESS. Thirty-eight percent of
participants were accordingly classified as having ESS.
Statistics
PASW 23.0 (IBM-SPSS Inc., Chicago, Il, USA) was used
for statistical analysis. The participants’ characteristics were
expressed as the mean, standard deviation and range of values
(Table 1). Multiple linear regression analysis was used to identify
the influence of UPDRS-III, SN+, hyposmia, depression, RBD
and the probability score for prodromal PD on ESS. Models
were adjusted for age, gender and physical activity. The level of
significance was set at 5%.
RESULTS
Characteristics of participants are shown in Table 1. In our
sample, more male (59%) than female participants were
recruited. The meanMDS UPDRS-III values were approximately
one point. The frequency of SN+ was approximately 2.5
times higher in males (24%) than in females (10%). A similar
distribution was observed for hyposmia (38% vs. 26%). The
frequency of depression in females (31%) was almost three times
higher than in males (13%). As expected, mean grip force and
mean muscle mass index were lower in females (26 kg, 8 kg/m2)
than in males (43 kg, 10 kg/m2).
TABLE 1 | Participant’s characteristics.
Male Female All p-valuea
(n = 150) (n = 105)
Age [years] 65.1 ± 5.4 64.7 ± 6.6 64.9 ± 5.9 0.611
Gender [%] 59 41 100 0.005b
UPDRS-III [p] 1.3[0–29] 0.9[0–20] 1.1[0–29] 0.290
SN positive [%] 24.0 9.5 18.0 0.010b
RBD [%] 8.0 8.6 8.2 0.870b
Depression [%] 13.3 31.4 20.8 0.000b
Hyposmia [%] 38.0 25.7 33.3 0.037b
PS for prodromal PD 4.9[0.03–83.2] 1.3[0.02–10.7] 3.4[0.02–83.2] 0.001
Gripforce [kg] 43 ± 7.0 26 ± 5.5 36.0 ± 10.7 0.000
Gait speed [m/s] 1.4 ± 0.2 1.3 ± 0.1 1.4 ± 0.2 0.000
Muscle mass index
[kg/m2]
10 ± 1.0 8 ± 0.9 9 ± 1.7 0.000
Body Mass Index [kg/m2] 28 ± 3.9 27 ± 5.1 28 ± 4.4 0.561
Physical activity score [p] 2.5 ± 1.3 2.4 ± 1.1 2.5 ± 1.2 0.934c
Values show mean and SD/range where appropriate. PS for prodromal PD: Probability
score for prodromal PD.
aT-test for independent samples.
bChi-square test.
cMann-Whitney U Test.
Results from the logistic regression are shown in Table 2.
The MDS UPDRS-III score was significantly associated with
ESS. The result remained significant after the adjustment for
age, gender and physical activity. No significant association
was found between ESS and the following parameters:
SN+, hyposmia, depression, RBD and probability score for
prodromal PD.
DISCUSSION
The main finding of this study is that in this basically
community-dwelling cohort aged approximately 65 years old
with an increased prevalence of people with risk factors for
PD but no clinical signs of PD, ESS was associated with subtle
motor features that were detectable with the MDS UPDRS-
III. The result indicates that ESS is associated with subtle
motor deficits in prodromal PD in at least a proportion of
individuals.
To date, neurodegenerative diseases are mainly defined
by the dysfunction of relatively circumscribed neuronal
systems. For example, for PD, it is mainly the nigrostriatal
degeneration that causes motor dysfunction, and for motor
neuron disease (MND), it is the degeneration of the upper
and lower motor neurons that causes weakness. Most of the
neurodegenerative diseases are, in addition to exhibiting the
“typical” features, characterized by a loss of muscle mass
and a decrease in functional performance. This association
makes it tempting to speculate about overlaps between
neurodegeneration and sarcopenia. In fact, recent investigations
have identified a relationship between low numbers of motor
neurons and sarcopenia (Drey et al., 2014), and suggest
the presence of neurodegenerative components that lead to
sarcopenia. Interestingly, Uitti and colleagues introduced the
term “neurodegenerative overlap syndrome,” which includes
PD, MND, and even dementia, more than 20 years ago (Uitti
et al., 1995). In conjunction with our data, the existence of
an “extended neurodegenerative overlap syndrome” that also
comprises sarcopenia should be considered. This hypothesis is
visualized in Figure 1.
The significant and exclusive association of the MDS UPDRS-
III score with the ESS indicates a relation of ESS with late
phases of prodromal PD. As shown in previous studies, motor
deficits present relatively close to clinical diagnosis (Maetzler and
Hausdorff, 2012; Schrag et al., 2015). This late occurrence of
motor features is different to most of the non-motor features,
which can precede clinical PD by more than a decade. The lack
of a relevant association between the ESS and prodromal PD
probability scores indirectly supports this conclusion, as only one
10th of the markers defining the prodromal PD probability score
refer to motor deficits (Berg et al., 2015).
This link between PD and sarcopenia in their earliest stages as
observed here could be driven by neuroinflammation. Elevated
levels of circulating inflammatory mediators are detectable in
patients in the early stages of both PD and sarcopenia, with
overlap in at least some of the species (Scalzo et al., 2010). An
example is IL6. This cytokine has been associated with the loss
of muscle mass and poor physical performance in older adults
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TABLE 2 | Logistic regression with ESS as dependent variable.
Model 1 Model 2 Model 3
Odds ratio p-value Odds ratio p-value Odds ratio p-value
UPDRS-III 2.609 [1.223; 5.563] 0.013 2.273 [1.046; 4.938] 0.038 2.309 [10.058; 5.037] 0.035
SN positive 0.871 [0.447; 1.698] 0.686 0.792 [0.395; 1.590] 0.512 0.795 [0.395; 1.600] 0.520
RBD 0.964 [0.384; 2.418] 0.938 0.969 [0.381; 2.464] 0.948 0.973 [0.382; 2.477] 0.954
Depression 1.040 [0.559; 1.933] 0.902 0.981 [0.511; 1.883] 0.955 0.986 [0.513; 1.894] 0.966
Hyposmia 0.734 [0.425; 1.266] 0.266 0.588 [0.328; 1.053] 0.074 0.608 [0.339; 1.092] 0.096
PS for prodromal PD 1.012 [0.984; 1.040] 0.397 1.000 [0.970; 1.030] 0.989 1.000 [0.970; 1.031] 0.997
UPDRS-III: Unified Parkinson’s disease rating scale, SN: Substantia nigra, RBD: REM-sleep behaviour disorder, PS for prodromal PD: Probability score for prodromal PD. Model 1:
unadjusted, Model 2: adjusted for age and gender, Model 3: adjusted for age, gender and physical activity.
FIGURE 1 | Extended neurodegenerative overlap syndrome. NMJ: neuromuscular junction.
(Cesari et al., 2004) and in PD (Scalzo et al., 2010). Another driver
could be the increased energy expenditure in PD due to muscular
rigidity and tremor. A significantly lower fat-free mass, but a
similar resting metabolic rate compared to controls, was found
in PD patients, which suggests the presence of a hypermetabolic
state in the latter cohort (Poehlman et al., 1995).
This study faces some limitations. First, we are not able
to determine whether further, not yet considered parameters
could explain our finding. For example, it could be that physical
inactivity is at least indirectly (e.g., through the metabolic
syndrome) related to the development of PD (LaHue et al., 2016),
and physical inactivity is certainly associated with lower muscle
mass. Although we included physical activity as a covariable in
our model, future studies should investigate such interactions in
more detail and with quantitative measures. A second limitation
could be the method that was used to estimate muscle mass.
Dual energy x-ray absorptiometry (DXA) is considered to be the
gold standard for that approach. Nevertheless, the BIA that was
used in our study appears to be an adequate alternative. Method
comparisons between BIA and DXA to determine muscle mass
showed a good correlation. Based on this, muscle mass that was
calculated using Janssen’s regression formula exhibited a strong
correlation (r= 0.906) with the muscle mass that was determined
by DXA (Bosaeus et al., 2014).
CONCLUSION
The association between MDS UPDRS-III and ESS in this cohort
with increased PD risk suggests a common pathway during
preclinical stages of both diseases. Moreover, EES may be a
prodromal marker of PD.
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